Nuvalent Dirección

Dirección controles de criterios 3/4

El CEO de Nuvalent's es Jim Porter , nombrado en Feb 2020, tiene una permanencia de 4.17 años. compensación anual total es $5.21M, compuesta por 11.1% salario y 88.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de $4.98M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 3.3 años, respectivamente.

Información clave

Jim Porter

Chief Executive Officer (CEO)

US$5.2m

Compensación total

Porcentaje del salario del CEO	11.1%
Permanencia del CEO	4.3yrs
Participación del CEO	0.1%
Permanencia media de la dirección	2.9yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jim Porter en comparación con los beneficios de Nuvalent?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$126m
Sep 30 2023	n/a	n/a	-US$114m
Jun 30 2023	n/a	n/a	-US$100m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$5m	US$580k	-US$82m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$57m
Dec 31 2021	US$5m	US$424k	-US$46m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$759k	US$335k	-US$15m

Compensación vs. Mercado: La compensación total ($USD5.21M) de Jim está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD6.59M).

Compensación vs. Ingresos: La compensación de Jim ha aumentado mientras la empresa no es rentable.

CEO

Jim Porter (47 yo)

4.3yrs

Permanencia

US$5,214,596

Compensación

Dr. James R. Porter, also known as Jim, Ph.D. has been Chief Executive Officer and President of Nuvalent, Inc. since February 1, 2020 and has been Director since February 2020. He joined Nuvalent during co...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
James Porter	CEO, President & Director	4.3yrs	US$5.21m	0.12% $ 5.2m
Matthew Shair	Founder	7.3yrs	US$360.39k	2.75% $ 122.3m
Alexandra Balcom	CFO & Treasurer	3.3yrs	US$2.02m	sin datos
Christopher Turner	Chief Medical Officer	3.2yrs	US$2.08m	0.022% $ 999.5k
Benjamin Lane	Senior Vice President of Technical Operations	1.8yrs	sin datos	sin datos
Deborah Miller	Chief Legal Officer & Secretary	2.9yrs	US$1.69m	0.052% $ 2.3m
Matthew Metivier	Senior Vice President of Human Resources	2.2yrs	sin datos	sin datos
Darlene Noci	Chief Development Officer	3.3yrs	sin datos	0.052% $ 2.3m
Henry Pelish	Senior Vice President of Drug Discovery	1.3yrs	sin datos	sin datos
John Soglia	Senior Vice President of Translational Development	1.3yrs	sin datos	sin datos
Perrin Wilson	Senior Vice President of Business Development & Strategy	less than a year	sin datos	sin datos

2.9yrs

Permanencia media

47yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NUVL se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
James Porter	CEO, President & Director	4.3yrs	US$5.21m	0.12% $ 5.2m
Matthew Shair	Founder	7.3yrs	US$360.39k	2.75% $ 122.3m
Sapna Srivastava	Independent Non-Executive Director	2.8yrs	US$171.95k	0% $ 0
Anna Protopapas	Independent Chairman	2.2yrs	US$553.69k	0% $ 0
Pasi Antero Janne	Member of Scientific Advisory Board	no data	sin datos	sin datos
D. Gilliland	Independent Non-Executive Director	3.3yrs	US$174.18k	0% $ 0
Michael Meyers	Independent Director	1.6yrs	US$366.82k	0% $ 0
Cameron Wheeler	Independent Non-Executive Director	7.3yrs	US$181.72k	sin datos
Joseph Pearlberg	Independent Non-Executive Director	3.3yrs	US$168.39k	sin datos
Emily Conley	Independent Director	2.3yrs	US$523.96k	0.000010% $ 444.2
D. Camidge	Member of Scientific Advisory Board	no data	sin datos	sin datos
Aaron Hata	Member of Scientific Advisory Board	no data	sin datos	sin datos

3.3yrs

Permanencia media

54yo

Promedio de edad

Junta con experiencia: La junta directiva de NUVL se considera experimentada (3.3 años de antigüedad promedio).

Nuvalent Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Independent Director notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Chief Legal Officer & Secretary notifies of intention to sell stock

Recent updates

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Price target increased by 10% to US$102

Independent Director notifies of intention to sell stock

Price target increased by 8.6% to US$92.13

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Price target increased by 7.4% to US$84.83

Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

New minor risk - Share price stability

Price target increased by 11% to US$59.14

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors

New major risk - Revenue and earnings growth

Price target increased by 8.7% to US$50.83

Chief Legal Officer & Secretary notifies of intention to sell stock

Price target increased by 8.7% to US$50.80

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Chief Development Officer exercised options and sold US$125k worth of stock

Price target increased by 10% to US$46.75

Chief Development Officer exercised options and sold US$113k worth of stock

Chief Development Officer exercised options and sold US$77k worth of stock

Chief Development Officer exercised options and sold US$86k worth of stock

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer exercised options and sold US$85k worth of stock

Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock

Chief Development Officer exercised options and sold US$121k worth of stock

Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Chief Development Officer exercised options and sold US$130k worth of stock

Price target increased to US$43.67

High number of new directors

Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock

Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Chief Development Officer exercised options and sold US$85k worth of stock

Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial

Chief Development Officer exercised options and sold US$72k worth of stock

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent, Inc. Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent, Inc. Presents New Preclinical Data Supporting Potential Best-In-Class Profile for ALK-Selective Inhibitor NV-655 At IASLC 2022 World Conference on Lung Cancer Annual Meeting

Nuvalent, Inc. Announces Leadership Promotions

Insider exercised options and sold US$278k worth of stock

Nuvalent, Inc.(NasdaqGS:NUVL) dropped from Russell 2000 Growth Index

Nuvalent, Inc. Announces Clinical Progress on Parallel Lead Programs NVL-520 and NVL-655 for NSCLC and Solid Tumor Cancers

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options to buy US$117k worth of stock.

Now 25% undervalued after recent price drop

Nuvalent, Inc., Annual General Meeting, Jun 16, 2022

High number of new directors

High number of new directors

Nuvalent, Inc. Appoints Anna Protopapas as Chair of Board of Directors

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Insider exercised options and sold US$68k worth of stock

Nuvalent Appoints Emily Drabant Conley to Board of Directors

Nuvalent, Inc Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo